Home | Publications | Therapeutic | Oncology place holder
place holder place holder

Oncology

An Evaluation of Products and Technologies for Molecular Diagnostics within Oncology


Publication Date   May 2006
Publisher   HSB Consulting
Product Type   Report
Pages   154
ISBN Number   not applicable
Product Code   HBS020
Ask a question about this product?

Price £3,140.00

approximately: $5,867 | €3,982

Summary


Project Objectives

The primary objective of this report, compiled from an analysis of primary and secondary research data, is to provide an overview of the molecular diagnostics market for selected oncology markers in the country markets listed below.
• France
• Germany
• Italy
• United Kingdom
• USA

The following key issues have been addressed:

• Provide a reflective picture of the type and number of relevant testing institutions
• Which and how many parameters are tested (market size). Top 3 solid markers, top 3 lymphoid markers and emerging markers identified.
• Which assays are used (home brew or commercial)
• Current market growth per parameter
• Expected market growth rates per parameter in the next 5 years
• Which technologies are used (PCR, RT-PCR, FISH, sequencing, microarrays, others) and what is the anticipated shift in use of these.
• Devices used
• The regulatory issues per country (legislation, reimbursement etc.)
• Future trends & emerging technologie

Content


Introduction

Part 1 – France

1 Current Situation
1.1 Respondent Population France
1.2 Nucleic Acid Based Testing
1.3 Genetic Testing - Routine or Research
1.4 HPV Testing
1.5 Oncology Markers
1.5.1 Solid Tumor Marker
1.5.2 Lymphoid Tumour Marker
1.6 Nucleic Acid Sample Preparation
1.7 Trends in NA-Based Oncology Diagnostics
1.7.1 Emerging Markers
1.7.2 CE approval
1.8 NAT - application and technical appraisal
1.9 Politics and Reimbursement
1.9.1 Drivers of NAT
1.9.2 Restraints on NAT
1.10 Summary and Conclusions

Part 2 – Germany

2 Current Situation
2.1 Respondent Population Germany
2.2 Nucleic Acid Based Testing
2.3 Genetic Testing - Routine or Research
2.4 HPV Testing
2.5 Oncology Markers
2.5.1 Solid Tumor Marker
2.5.2 Lymphoid Tumor Marker
2.6 Nucleic Acid Sample Preparation
2.7 Trends in Genetics Based Oncology Diagnostics
2.7.1 Emerging Markers
2.7.2 CE certification
2.8 NAT - application and technical appraisal
2.9 Politics and Reimbursement
2.9.1 Drivers of NAT
2.9.2 Restraints on NAT
2.10 Summary and Conclusions

Part 3 – Italy

3 Current Situation
3.1 Respondent Population – Italy
3.2 Nucleic Acid Based Testing
3.2.1 Types of testing performed
3.3 Genetic Testing - Routine or Research
3.4 HPV Testing
3.5 Oncology Markers
3.5.1 Solid Tumor Marker
3.5.2 Lymphoid Tumor Marker
3.6 Nucleic Acid Sample Preparation
3.7 Trends in NA-Based Oncology Diagnostics
3.7.1 Emerging Markers
3.7.2 CE or FDA approval
3.8 NAT - application and technical appraisal
3.9 Politics and Reimbursement
3.9.1 Drivers of NAT
3.9.2 Restraints on NAT
3.10 Summary and Conclusions

Part 4 – United Kingdom

4 Current Situation
4.1 Respondent Population UK
4.2 Nucleic Acid Based Testing
4.3 Genetic Testing - Routine or Research
4.4 HPV Testing
4.5 Oncology Markers
4.5.1 Solid Tumor Marker
4.5.2 Lymphoid Tumor Marker
4.6 Nucleic Acid Sample Preparation
4.7 Trends in NA-Based Oncology Diagnostics
4.7.2 Emerging Markers
4.7.3 CE certification
4.8 NAT - application and technical appraisal
4.9 Politics and Reimbursement
4.9.1 Drivers of NAT
4.9.2 Restraints on NAT
4.10 Summary and Conclusions

Part 5 – USA

5 Current Situation
5.1 Respondent Population US
5.2 Nucleic Acid Based Testing
5.2.1 Types of testing performed
5.3 Genetic Testing - Routine or Research
5.4 HPV Testing
5.5 Oncology Markers
5.5.1 Solid Tumor Marker
5.5.2 Lymphoid Tumor Marker
5.6 Nucleic Acid Sample Preparation
5.7 Trends in NA-Based Oncology Diagnostics
5.7.1 Emerging Marker
5.7.2 Test Certification
5.8 NAT - application and technical appraisal
5.9 Politics and Reimbursement
5.9.1 Drivers of NAT
5.9.2 Restraints on NAT
5.10 Summary and Conclusions